For patients with SLE, is there an ANC level for which you would hold or adjust hydroxychloroquine in an asymptomatic patient?
Leukopenia most often as lymphocytopenia, of course, is not unusual in lupus. Total WBC less than 4000 is an ACR classification criteria for the disease as is ALC less than 1500 on two occasions. SLICC disease classification requires ALC less than 1000. Total WBC < 3000 generates SLEDAI points. On the other hand, neutropenia is much less common as a manifestation of disease and it's not part of any of the three classification criteria. With that said, there is a neutrophil associated antibody assay which suggests antibody mediated consumption similar to the DAT or Coombs assay for autoimmune hemolytic anemia and platelet associated antibody as seen in AITP. Coincidentally, I ordered this test several times recently in my lupus patients with neutropenia and found it not infrequently to be positive. Regardless, drug-induced neutropenia can be an issue in our patients with SLE including in patients on immunosuppressive meds that may inhibit bone marrow hematopoiesis. Neutropenia on the basis of hydroxychloroquine, however, likely occurs very rarely and in less than one percent of patients. Agranulocytosis occurs only at the case report level. Given all the benefits associated with hydroxychloroquine use in our lupus patients, I would be reluctant to discontinue in the face of neutropenia unless there was strong evidence for causation in the problem. For example, would prefer withdrawal and confirmation by rechallenging.
While one can never completely exclude any drug as a potential cause of neutropenia, in 36 years of practice managing SLE patients, I have never encountered a bona fide case of HCQ-induced neutropenia (i.e. resolution with holding the drug and recurrence following re-introduction). As such, when neutropenia occurs in an SLE patient on HCQ the working assumption is that this is most likely disease-related or perhaps related to another drug the patient may be taking (immunosuppressive or other drugs for which associations with neutropenia have been observed in contexts other than SLE).